H.C. Wainwright lowered the firm’s price target on Co-Diagnostics to $1.50 from $2 and keeps a Neutral rating on the shares following the Q2 report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CODX:
- Co-Diagnostics reports Q2 EPS (25c) vs. (31c) last year
- Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results
- Co-Diagnostics expands vector control customer base to 25 across 15 states
- Co-Diagnostics submits FDA 510(k) application for Co-Dx PCR Pro platform
- Co-Diagnostics completes first FDA 510(k) application for Co-Dx PCR Pro